Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Condition(s) targeted: Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes

Intervention: Sorafenib-Vorinostat (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: Indiana University School of Medicine

Official(s) and/or principal investigator(s):
Hamid Sayar, MD, Principal Investigator, Affiliation: Indiana University Melvin and Bren Simon Cancer Center

Overall contact:
Mary Cangany, RN, Phone: 317-274-2178, Email: mcangany@iupui.edu

The purpose of this study is to test the safety of sorafenib and vorinostat when given together to see what effects (good and bad) it has on the patient and their acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). This study is also being done to find the highest dose of sorafenib and vorinostat that can be given together without causing severe side effects.

Official title: Phase I, Open-label, Dose-escalation Study of the Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Study design: Treatment, Open Label, Single Group Assignment, Safety Study

Primary outcome: Determine the maximum tolerated dose of a combination of Sorafenib and Vorinostat administered to patients with poor-risk AML, or MDS with >10% blasts.

Secondary outcome:

Evaluate response and the duration of response to this combination targeted therapy

Evaluate the toxicity of the combination of Sorafenib and Vorinostat in patients receiving this therapy

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients must have a diagnosis of AML (> 20% myeloid blasts in the peripheral blood

or bone marrow) or MDS with > 10% myeloid blasts in the bone marrow. Patients with Acute Promyelocytic Leukemia (APL) must be refractory to all-trans retinoic acid (ATRA) and arsenic trioxide.

- The patients must have one of the following criteria:

- Age of 18 to 69 years; relapsed or refractory disease following at least one

prior therapeutic regimen; not a candidate for cytotoxic or other conventional therapies due to disease refractoriness, poor performance status, or co-morbidities

- Age of 70 years or older; received no previous therapies (other than

hematopoietic growth factors or hydroxyurea); not a candidate for cytotoxic or other conventional therapies due to poor performance status, co-morbidities, or personal preference

- Age of 70 years or older with relapsed or refractory disease

- The patient must have discontinued all previous therapies for acute leukemia for at

least 14 days and recovered from the acute effects of the therapy.

- Patients must have an ECOG (Zubrod) performance status of 0-2

- Patients must be able to take and tolerate oral medications

- Patients must have adequate organ function as specified in the protocol.

- Patients not on anti-coagulation must have an INR < 1. 5 and a PTT within normal

limits.

Exclusion Criteria:

- Pregnant women or nursing mothers are not eligible for this trial.

- Patients may receive no other concurrent biologic therapy, cytotoxic chemotherapy or

radiation therapy during this trial.

- Patients with one or more serious preexisting medical conditions that, in the opinion

of the investigator, would preclude participation in this study. See protocol for listing.

- Patients with known central nervous system (CNS) leukemia by spinal fluid cytology,

flow cytometry or imaging

- Patients with previous autologous or allogeneic stem cell transplantation who have

current side effects and/or complications that in the opinion of the investigator can interfere with the interpretation of the toxicities.

Mary Cangany, RN, Phone: 317-274-2178, Email: mcangany@iupui.edu

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana 46202, United States; Recruiting
Mary Cangany, RN, Phone: 317-274-2178, Email: mcangany@iupui.edu
Hamid Sayar, MD, Phone: 317-274-7126, Email: ssayar@iupui.edu
Hamid Sayar, MD, Principal Investigator

Find a Clinical Trial- Click "Leukemia (Adult)" -Click "IUCRO-0234"

Starting date: April 2009
Ending date: April 2014
Last updated: October 7, 2009